Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV‐1 null responders
Enrico Galmozzi, Alessio Aghemo, Massimo Colombo – 28 June 2012
Targeting chromatin remodelers to treat hepatocellular carcinoma
Manlio Vinciguerra – 28 June 2012
Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value
Puneeta Tandon, Michael Ney, Ivana Irwin, Mang M. Ma, Leah Gramlich, Vincent G. Bain, Nina Esfandiari, Vickie Baracos, Aldo J. Montano‐Loza, Robert P. Myers – 27 June 2012 – As detected by cross‐sectional imaging, severe muscle depletion, which is termed sarcopenia, holds promise for prognostication in patients with cirrhosis. Our aims were to describe the prevalence and predictors of sarcopenia in patients with cirrhosis listed for liver transplantation (LT) and to determine its independent prognostic significance for the prediction of waiting‐list mortality.
Living donor liver transplantation for hepatorenal syndrome: To do or not to do? That is the question
Mitra K. Nadim, Randall S. Sung – 27 June 2012
ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: A systematic review and meta‐analysis
Emilio Rodrigo, Marcos López‐Hoyos, Mario Corral, Emilio Fábrega, Gema Fernández‐Fresnedo, David San Segundo, Celestino Piñera, Manuel Arias – 27 June 2012 – Immune status monitoring of transplant recipients could identify patients at risk of acute rejection, infection, and cancer, which are important sources of morbidity and mortality in these patients. The ImmuKnow assay provides an objective assessment of the cellular immune function of immunosuppressed patients.
Rapid recovery of cytochrome P450 3A4 after protease inhibitor withdrawal in post–liver transplant patients
Ye Htun Oo, David J. Mutimer – 27 June 2012
Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation
- Read more about Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation
Deepa T. Patil, Lisa M. Yerian – 27 June 2012 – Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is the fourth most common indication for liver transplantation. Risk factors for NAFLD can persist and even worsen after liver transplantation. However, the risk and significance of NAFLD recurrence remain unclear. Reported posttransplant NAFLD and NASH recurrence rates vary widely across studies.
Rapid response activatable molecular probes for intraoperative optical image‐guided tumor resection
Samuel Achilefu – 26 June 2012
Use of higher thromboelastogram transfusion values is not associated with greater blood loss in liver transplant surgery
Shen‐Chih Wang, Ho‐Tien Lin, Kuang‐Yi Chang, M. Susan Mandell, Chien‐Kun Ting, Ya‐Chun Chu, Che‐Chuan Loong, Kwok‐Hon Chan, Mei‐Yung Tsou – 23 June 2012 – Plasma‐containing products are given during the pre‐anhepatic stage of liver transplant surgery to correct abnormal thromboelastogram (TEG) values and prevent blood loss due to coagulation defects. However, evidence suggests that abnormal TEG results do not always predict bleeding. We questioned what effect using higher TEG values to initiate treatment would have on blood loss.
Investigation of residual hepatitis C virus in presumed recovered subjects
Kei Fujiwara, Robert D. Allison, Richard Y. Wang, Patricia Bare, Kentaro Matsuura, Cathy Schechterly, Krishna Murthy, Francesco M. Marincola, Harvey J. Alter – 23 June 2012 – Recent studies have found hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells (PBMCs) of the majority of presumed recovered subjects. We investigated this unexpected finding using samples from patients whose HCV RNA and anti‐HCV status had been serially confirmed. HCV RNA was detected in PBMCs from 66 of 67 chronic HCV carriers.